Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone Palmitate for Schizophrenia in Rwanda
NCT04940039Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Apr 2024
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical Global Impression - Severity for Schizophrenia. Started Jul 2021; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04940039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940039.